Talarn Carme, Urbano-Ispizua Alvaro, Martino Rodrigo, Pérez-Simón José Antonio, Batlle Montserrat, Herrera Concepción, Granell Miquel, Gaya Anna, Torrebadell Montserrat, Fernández-Avilés Francesc, Aymerich Marta, Marín Pedro, Sierra Jorge, Montserrat Emili
Institute of Hematology and Oncology, Department of Hematology, H. Clínic, Barcelona , Spain.
Haematologica. 2007 Dec;92(12):1655-63. doi: 10.3324/haematol.11076.
Dendritic cells (DC) play a critical role in the regulation of alloimmune responses and might influence the outcome of allogeneic stem cell transplantation (allo-SCT). We studied the clinical relevance of early reconstitution of DC after reduced-intensity conditioning allo-SCT (allo-RIC).
This study included 79 adult patients undergoing allo-RIC from HLA-identical siblings. Peripheral blood samples were drawn from patients at 1 month (+1m) and 3 months (+3m) after the transplant. DC were identified as positive for HLA-DR and negative for CD3, CD19, CD14 and CD56. The expression of CD33, CD123 and CD16 was used to identify myeloid DC, plasmacytoid DC and CD16(+) DC subpopulations, respectively.
Patients whose DC count at +1m was lower than the median had a higher probability of treatment-related mortality (TRM) (60% vs 12%; p=0.02), poorer overall survival (OS) (15% vs 45%; p=0.002) and worse event-free survival (EFS) (20% vs 38%; p=0.03). A multivariate analysis confirmed that low DC counts had a detrimental effect on OS (RR 3.2; p=0.007), relapse (RR 4.1; p=0.01), and EFS (RR 6; p=0.001). Low CD16(+) DC counts were observed to have a detrimental effect on EFS, which was due to both a higher incidence of deaths caused by infections (50% vs 0%, p=0.05) and a higher incidence of relapse (57% vs 50%; p=0.03). Indeed, the number of CD16(+) DC at +3 m was the most important prognostic factor for EFS (RR 6; p=0.001). Interpretations and Conclusions This study shows the clinical importance of DC recovery, especially of the CD16(+) DC subset, in the outcome of patients treated with allo-RIC.
树突状细胞(DC)在同种异体免疫反应调节中起关键作用,可能影响异基因干细胞移植(allo - SCT)的结果。我们研究了低强度预处理异基因干细胞移植(allo - RIC)后DC早期重建的临床相关性。
本研究纳入了79例接受来自 HLA 配型相合同胞的 allo - RIC 的成年患者。在移植后1个月(+1m)和3个月(+3m)采集患者外周血样本。DC 被鉴定为 HLA - DR 阳性且 CD3、CD19、CD14 和 CD56 阴性。分别用 CD33、CD123 和 CD16 的表达来鉴定髓样 DC、浆细胞样 DC 和 CD16(+) DC 亚群。
移植后1个月时 DC 计数低于中位数的患者发生治疗相关死亡率(TRM)的概率更高(60% 对 12%;p = 0.02),总生存期(OS)更差(15% 对 45%;p = 0.002),无事件生存期(EFS)更差(20% 对 38%;p = 0.03)。多因素分析证实,低 DC 计数对 OS(风险比[RR] 3.2;p = 0.007)、复发(RR 4.1;p = 0.01)和 EFS(RR 6;p = 0.001)有不利影响。观察到低 CD16(+) DC 计数对 EFS 有不利影响,这是由于感染导致的死亡发生率更高(50% 对 0%,p = 0.05)和复发发生率更高(57% 对 50%;p = 0.03)。实际上,移植后3个月时 CD16(+) DC 的数量是 EFS 最重要的预后因素(RR 6;p = 0.001)。解释与结论:本研究表明 DC 恢复,尤其是 CD16(+) DC 亚群的恢复,在接受 allo - RIC 治疗的患者预后中具有临床重要性。